OmniSeq News
Hitachi High-Tech Participates in OmniSeq Series B and Secures Japanese Distribution Rights
BUFFALO, NEW YORK – April 12, 2018 – OmniSeq® , a molecular diagnostics subsidiary of the Roswell Park Comprehensive Cancer Center, announced today Hitachi High-Technologies Corporation (TOKYO: 8036, Hitachi High-Tech)’s participation in OmniSeq’s Series B financing...
read moreOmniSeq & LabCorp Launch Tumor-Only MSI NGS Assay
BUFFALO, NEW YORK – April 16, 2018 – OmniSeq®, a molecular diagnostics subsidiary of the Roswell Park Comprehensive Cancer Center, and LabCorp® (NYSE: LH), a leading global life sciences company, announced today the commercial launch of OmniSeq MSI NGS, a tumor-only,...
read moreOmniSeq Receives CAP Accreditation and Publishes Analytical Validation Paper
Important Achievements Validate OmniSeq’s High Quality Laboratory Practices and Immune Report Card Assay Buffalo, NY – NOVEMBER 9, 2017 – OmniSeq, Inc., a molecular diagnostics subsidiary of the Roswell Park Cancer Institute, announced today that it...
read moreOmniSeq and LabCorp Sign Exclusive Distribution Agreement and Series B Funding Commitment
Marcia Eisenberg, Chief Scientific Officer of LabCorp Diagnostics, to Join OmniSeq’s Board of Directors BUFFALO, N.Y., Aug. 21, 2017 (GLOBE NEWSWIRE) -- OmniSeq, Inc., a molecular diagnostics subsidiary of the Roswell Park Cancer Institute, announced today...
read moreLaunch of Immune Report Card
BUFFALO, N.Y., June 14, 2017 (GLOBE NEWSWIRE) -- OmniSeq, an innovation of Roswell Park Cancer Institute, announced today the commercial launch of Immune Report Card SM, the first immune profiling test designed to help oncologists select the best mono and...
read moreTumor Genetics & Cancer Research
Dr. Lucio Miele from LSU School of Medicine talks about the benefits of the recent partnership with OmniSeq on WVUE FOX 8 News in New Orleans
read moreOmniSeq Forms Clinical Evaluation Partnership with LSU Health New Orleans to Provide Comprehensive Genomic Profiling
NEW ORLEANS, LOUISANA – November 10, 2016 – Louisiana State University Health Sciences Center New Orleans ( LSU Health New Orleans) and Omniseq (OmniSeq®), a subsidiary of the Roswell Park Cancer Institute (RPCI), are now partnering to provide oncologists with...
read moreOmniSeq Presents Benefits of Immune Cancer Profiling at Association of Molecular Pathology (AMP) with Thermo Fisher Scientific
THERMO FISHER SCIENTIFIC (TMO) EXPANDS PORTFOLIO OF NEXT-GENERATION SEQUENCING CANCER RESEARCH ASSAYS New Oncomine products enable immune response analysis of the tumor microenvironment, interrogation of BRCA 1-2 genes, and liquid biopsy research using cell-free DNA...
read moreOmniSeq Receives New York CLEP Approval for 144 Gene Comprehensive Panel and Partners with Cure Forward to Advance Precision Medicine for Cancer Patients
BUFFALO, NY – June 28, 2016 – OmniSeq, a subsidiary of Roswell Park Cancer Institute, received New York State Clinical Laboratory Evaluation Program (CLEP) approval for its OmniSeq ComprehensiveSM panel, a 144 gene, pan-cancer, next-generation sequencing (NGS) tumor...
read moreOmniSeq Appoints Genomics Industry Veteran Mark Gardner as CEO and Board of Directors Member
BUFFALO, N.Y., March 31, 2016 /PRNewswire/ — OmniSeq LLC today announced the appointment of biotech industry veteran Mark Gardner as CEO and member of its Board of Directors. His role will be effective in April after he transitions from his executive...
read more
Follow Us on Twitter
Thanks to all of our collaborators (9 Institutions @RoswellPark, @FoxChaseCancer, @columbiacancer, @WeillCornell and others) that contributed to the Melanoma Immune Landscape paper pushing our understanding of prediction to response to immune therapy.
https://t.co/XDSA8jDWf4